InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,771.67
(
1.03%
)
US TECH 100
19,694.65
(
1.31%
)
Dow Jones
42,159.76
(
0.87%
)
Brent Oil
75.19
(
0.09%
)
Bitcoin
69,987.03
(
3.20%
)
Post# of 253533
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120669
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 178037

Wednesday, 03/22/2017 9:43:58 AM

Wednesday, March 22, 2017 9:43:58 AM

Post# of 253533
NVS’ Serelaxin fails revamped phase-3 trial in acute HF:

https://www.sec.gov/Archives/edgar/data/1114448/000117184317001675/f6k_032217.htm

Serelaxin appers to be dead in the water. The FDA rejected it in May 2014 (#msg-102108200) following a negative advisory panel (#msg-99602449). The European MAA was also withdrawn.

This case is a reminder that BTD (which Serelaxin had) does not ensure regulatory success.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up